Patient Access and Metastatic Prostate Cancer Therapy
Dr Morgans discusses how patient access impacts treating metastatic prostate cancer.
EP: 1.Diagnosing Metastatic Prostate Cancer
EP: 2.Biomarker Testing in Metastatic Prostate Cancer
EP: 3.Treatment Options for Metastatic Prostate Cancer
EP: 4.The Role of PARP Inhibitors in Prostate Cancer
EP: 5.Rucaparib for Prostate Cancer
EP: 6.Advances in Metastatic Castration-Resistant Prostate Cancer
EP: 7.Routinely Ordered Testing for Metastatic Prostate Cancer
EP: 8.Biomarker Testing Protocols for Metastatic Prostate Cancer and What to Look For
EP: 9.BRCA1/2 in Metastatic Prostate Cancer
EP: 10.Systemic Treatment Options for Metastatic Castration-Resistant Prostate Cancer
EP: 11.Selecting Appropriate Treatment and Monitoring Patients on Metastatic Prostate Cancer Therapy
EP: 12.The Role of PARP Inhibitors and Adverse Events in Metastatic Prostate Cancer Therapy
EP: 13.Other Factors Considered When Adding PARP Inhibitors to Metastatic Prostate Cancer Therapy
EP: 14.Patient Access and Metastatic Prostate Cancer Therapy
EP: 15.Sequencing Strategies for Metastatic Castration-Resistant Prostate Cancer Therapy
EP: 16.Exciting Advances in the Therapeutic Space and Clinical Pearls for Treating Metastatic Prostate Cancer
EP: 17.Recap: Recommendations for PARP Inhibitor Use in Prostate Cancer
EP: 18.Recap: Testing and Treating Metastatic Castration-Resistant Prostate Cancer
Matthew Fowler: Is patient access a factor when considering the best treatment, whether it be cost, travel, or the availability of a caregiver?
Alicia Morgans, MD, MPH: Patient access is always one of the most important things that we have to think about. The treatment doesn’t work if a patient can’t get the treatment and it’s still in the bottle, in the bag, or at the pharmacy. We need to get the treatment to the patient. One of the things that’s most important when we think about the difference between efficacy in a clinical trial and effectiveness in a real-world population is this barrier, this access issue that can absolutely limit patients from getting treated.
If a patient can’t come to the clinic and get their infusion for chemotherapy, it’s not going to be effective. Or if a patient can’t get prior authorization to have access to a PARP inhibitor, even if he has a mutation that should be sensitive to that PARP inhibitor, it’s not going to be effective. These are absolutely things we need to think about. And each treatment has its own necessities. Whether it’s traveling to the clinic, monitoring for cytopenias, or a co-pay, each treatment is going to have specific aspects that can limit access. We as clinicians need to think about that and ensure that we resolve as many as possible to ensure that we get our patients the treatments that they need.
This transcript has been edited for clarity.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
